Clinical trials: CMS
Diabetes Mellitus, Type 2, Chronic Disease
Impact of CMS Reimbursement Policy Supporting Care Coordination in Louisiana
Investigators propose to use a natural experiment design to examine the impacts of the new CPT code (99490) for chronic care management on health outcomes.
- Trial name
- NCT03136471
- Where
- United States
- Volunteers
- 22,242 people, healthy volunteers welcome
- Sponsor
- Tulane University
Healthy Volunteers
Study on the Mass Balance of [14C] CMS-D002 in Healthy Adult Participants in China
This phase 1, single-group study will evaluate the mass balance of [14C] CMS-D002 after a single oral dose in healthy adult participants in China.
- Trial name
- NCT07788482
- Testing
- [14C] CMS-D002
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Evaluate the Safety and Tolerability, Healthy and Overweight or Obese Participants
Phase 1 Study of Ascending Doses of CMS-D008 in Healthy and Overweight/Obese Adults
This study is a first-in-human clinical trial of CMS-D008 conducted in Chinese healthy and overweight or obese adult participants, consisting of three parts: Part-1 Single Ascending Dose (SAD) study (hereinafter referred to as…
- Trial name
- NCT07518589
- Testing
- CMS-D008
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Chronic Ischemic Left Ventricular Dysfunction
Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction
This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary…
- Trial name
- HECTOR (NCT05068674)
- Testing
- Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells, Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells, Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Joseph C. Wu
Ischemic Heart Failure, CABG-patients
hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease
This is an exploratory study. A total of 16 patients meeting the inclusion and exclusion criteria and awaiting coronary artery bypass grafting (CABG) surgery will be enrolled.
- Trial name
- NCT07471698
- Testing
- HiCM-188 Chitosan Patch, Blank Chitosan Patch
- Where
- China
- Volunteers
- 16 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Healthcare Fraud Schemes, Kickback Networks
Healthcare Integrity & Anti-Fraud Enforcement
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities.
- Conditions
- Healthcare Fraud Schemes, Kickback Networks, Supply Chain Vulnerabilities, Governance Failures
- Trial name
- PHX-AFK-US (NCT07217730)
- Testing
- Validator-Governed Reform & Regulatory Escalation Protocol, Coalition-Grade Validator Dashboard Module (CVDM-1), Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Truway Health, Inc.
Heart Failure, Heart Failure At NYHA Stage III or IV
IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure
This clinical trial investigates the safety, feasibility, and therapeutic potential of a combined approach using HiCM-188 cardiomyocyte injection delivered intramyocardially alongside either LVAD implantation or CABG surgery in…
- Trial name
- NCT06866600
- Testing
- low dose CABG+iPSC-CMs, High dose CABG/LVAD+iPSC-CMs, CABG/LVAD+Saline
- Where
- China
- Volunteers
- 40 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Heart Failure
Treating Heart Failure With hPSC-CMs
Heart failure has a high morbidity and mortality because the heart is one of the least regenerative organs in the human body. Drug treatments for heart failure manage symptoms but do not restore lost myocytes.
- Trial name
- HEAL-CHF (NCT03763136)
- Testing
- hPSC-CM Therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Congenital Myasthenic Syndrome, CMS
A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)
The purpose of this study is to assess efficacy and safety of adimanebart in participants at least 12 years of age with DOK7-, MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS).
- Trial name
- CoMetS (NCT07746089)
- Testing
- Adimanebart IV
- Volunteers
- 105 people
- Sponsor
- argenx
Osteoarthritis, Degenerative Arthritis
Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting
The primary objective of the study is to determine how the short-term outcome of subjects implanted with the JOURNEY™ II BCS Total Knee System compares to subjects implanted with other PS total knee systems, and to determine if…
- Conditions
- Osteoarthritis, Degenerative Arthritis, Traumatic Arthritis
- Trial name
- NCT02820766
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Smith & Nephew, Inc.
Moderate to Severe Plaque Psoriasis
A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
This study adopted a multicenter, randomized, double-blind, placebo-controlled phase II/III operation seamless adaptive design, aiming to evaluate the efficacy, safety and tolerability of CMS-D001 tablets in the treatment of…
- Trial name
- NCT07432854
- Testing
- CMS-D001 50mg, CMS-D001 100mg
- Where
- 21 sites in China
- Volunteers
- 540 people
- Sponsor
- Dermavon Holdings Limited
Superficial Skin and Soft Tissue Infections Caused by Gram-positive Bacteria
A Phase I Clinical Trial to Evaluate CMS-F021 Following Single and Multiple Doses in Healthy Participants
"This study is a first-in-human (FIH) trial of CMS-F021 conducted in healthy Chinese adult participants, consisting of two parts: Part 1-a single ascending dose (SAD) study (referred to as Part 1 SAD), and Part 2-a multiple…
- Trial name
- NCT07790770
- Testing
- CMS-F021 Gel, Drug: CMS-F021 Gel healthy participant
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Dermavon Holdings Limited
Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
Primary: The primary objective of this study under the original protocol was to provide neuromuscular specialists and neurologists access to amifampridine phosphate therapy for their patients with LEMS, CMS or downbeat nystagmus…
- Conditions
- Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
- Trial name
- EAP-001 (NCT02189720)
- Testing
- Amifampridine Phosphate
- Where
- United States
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Mild Cognitive Impairment
Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II
A substantial portion of people covered by Medicare will develop Alzheimer's disease and other forms of dementia that together devastate the lives of millions of people in the United States, and cost us a total of over $200…
- Trial name
- NCT02317250
- Testing
- Amyloid imaging, FDG-PET
- Sponsor
- University of California, Los Angeles
Breast Cancer, Cervical Cancer
Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities
The goal of this behavioral research study is to improve the use of cancer prevention services, increase early detection, and treatment of cancer.
- Conditions
- Breast Cancer, Cervical Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT00453661
- Testing
- Questionnaire, Patient Navigator (PN)
- Where
- United States
- Volunteers
- 2,472 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial, aiming to evaluate the efficacy, safety, and tolerability of CMS-D001 in participants with moderate to severe atopic dermatitis…
- Trial name
- NCT07465120
- Testing
- CMS-D001 50mg, CMS-D001 100mg, CMS-D001 200mg
- Where
- 28 sites in China
- Volunteers
- 160 people
- Sponsor
- Dermavon Holdings Limited
Heart Failure
Treating Heart Failure With hiPSC-CMs
Heart failure has a high morbidity and mortality because the heart is one of the least regenerative organs in the human body. Drug treatments for heart failure manage symptoms but do not restore lost myocytes.
- Trial name
- NCT05223894
- Testing
- hiPSC-CM therapy, Control
- Where
- China
- Volunteers
- 20 people
- Sponsor
- HELP Therapeutics Co., Ltd.